Fate of EPO encourages pharmaceutical companies to collaborate with anti-doping officers

Today a lot of drug manufacturers are ready to collaborate with anti-doping agencies in their war on administration of forbidden medicines in sports. It sounds strange but this is the reality. In fact, if you review the fate of EPO, you can comprehend why pharmaceutical companies agree to support efforts of anti-doping officials. EPO is really an effectual remedy for treatment of anemia. Many persons with anemia that have applied EPO have been treated. But what do you think while hearing about this medicine? Almost each individual associates this remedy only with doping in sports. This preparation has been abused by the American cyclist Lance Armstrong that has cheated the whole world. Thus, EPO is associated only with cheating, shame, etc. Looking at this case, pharmaceutical companies try to “defend” their products from the similar fate. That’s why they work together with anti-doping agencies.
Although certain drug manufacturers started to cooperate with anti-doping officers long ago, sometimes there were several problems between them. Anti-doping officials criticized certain pharmaceutical companies for their connections with doping.
Today relations between anti-doping agencies and pharmaceutical companies are closer. Drug manufacturers share detailed information about new medicines with anti-doping agencies. It is precious information for development of detection tests for these medications. While anti-doping officials learn how medicines are manufactured, how they pass into body, how they work in the body, they can introduce more efficient tests for these drugs.
For example, the company Roche that elaborated the medication CERA helped anti-doping officers to elaborate a detection test for it. Later other pharmaceutical companies followed the example of Roche. The pharmaceutical company GlaxoSmithKline went so far, as it sponsored an anti-doping lab during Olympics in London.
While relations between anti-doping officers and big pharmaceutical companies become stronger, smaller pharmaceutical companies begin to cooperate with anti-doping agencies too. While previously pharmaceutical companies haven’t wanted to discuss about their relations with anti-doping agencies openly, nowadays they don’t fear to announce about this condition.